💬In plain words
What the trial is, and whether it could suit you
Background:
Clonal Hematopoiesis of Indeterminate Potential (CHIP) is a change in a person s DNA that can increase a person s risk of developing blood cancers or cardiovascular disease. CHIP occurs mostly occurs in older people. Clonal cytopenia of undetermined significance (CCUS) occurs when one or more blood cell types is lower than it should be and is associated with a change in their DNA. Researchers want to learn more about how CHIP and CCUS progress.
Objective:
To examine the natural history of people in a study of CHIP and CCUS to (1) verify the association of myeloid somatic mutations with atherosclerosis and blood cancers, and (2) find new potential clinical associations.
Eligibility:
Adults 18 and older with CHIP with a somatic pathogenic variant associated with blood cancers. Adults with CCUS are also needed.
Design:
Potential participants will be screened with gene tes
Sign in to get the eligibility rules as simple questions to take to your doctor.
📋 Eligibility rules (as published)
* Participants with Clonal Hematopoiesis of Indeterminate Significance (CHIP):
INCLUSION CRITERIA:
* Greater than or equal to 18 years of age
* Willingness and capacity to provide written informed consent
* Presence of a somatic pathogenic variant associated with hematological malignancy
* Variant allele fraction of greater than or equal to 2% in at least one identified somatic pathogenic variant
EXCLUSION CRITERIA:
* Known diagnosis of a hematological malignancy or bone marrow failure syndrome (excluding MGUS or MBL)
* Presence of a cytopenia:
--Hemoglobin, \<10 g/dL; platelet count, \<100 X 10\^9 /L; or absolute neutrophil count, \<1.5 X 10\^9 /L
* Pregnant at the time of recruitment
Participants with Clonal Cytopenia of Uncertain Significance (CCUS):
INCLUSION CRITERIA:
* Greater than 18 years of age
* Willingness and capacity to provide written informed consent
* Presence of a somatic pathogenic variant associated with hematological malignancy without morphological evidence of
myelodysplasia and without a MDS defining cytogenetic abnormality
* Variant allele fraction of greater than or equal to 2% in at least one identified somatic pathogenic variant
* Bone marrow aspirate and biopsy excluding hematological malignancy and MDS
* Presence of a cytopenia for \>30 days
* Hemoglobin, \<10 g/dL; platelet count, \<100 X10\^9 /L; or absolute neutrophil count, \<1.5 X10\^9 /L
* At least 2 CBCs documented in a non-hospitalized patient at least 3 days apart
EXCLUSION CRITERIA:
* Known diagnosis of a hematological malignancy or bone marrow failure syndrome (excluding MGUS or MBL)
* Morphological evidence of dysplasia on bone marrow aspirate / biopsy 10% dysplastic cells in any hematopoietic lineage
* Ringed sideroblasts \>15%
* Presence of MDS defining cytogenetic abnormality
* Del(7q)
* del(5q)
* 17q or t(17p)
* Del(13q)
* del(11q)
* del(12p) or t(12p)
* del(9q)
* idic(X)(q13)
* t(11;16)
* t(3;21)
* t(1;3)
* t(2;11)
* inv(3)/t(3;3)
* t(6;9)
--Note: As a sole cytogenetic abnormality in the absence of morphological criteria, gain of chromosome 8, del(20q) and loss of chromosome Y are not considered definitive evidence of MDS.
* Alternate hematological diagnosis causing cytopenia
* Pregnant at time of recruitment
National Institutes of Health Clinical Center
Bethesda, United States
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
HealthTeky